Trials / Completed
CompletedNCT01881191
Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months
Effect of Teriflunomide (Aubagio®) on Gray Matter Pathology in Multiple Sclerosis: The 12 Months, Prospective, Observational, Single-blinded, Longitudinal Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (actual)
- Sponsor
- University at Buffalo · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the effects of Aubagio on changes in the brain using MRI.
Detailed description
Patients who take Aubagio will have an MRI, eye test, have blood taken, and complete a questionnaire on environmental risk factors to evaluate changes in the brain and on disease progression. A healthy control group will also complete the same testing regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | MRI |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2015-10-01
- Completion
- 2015-10-01
- First posted
- 2013-06-19
- Last updated
- 2016-02-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01881191. Inclusion in this directory is not an endorsement.